Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848342 | 0.93 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL31316605 | 0.89 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17848607 | 0.86 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL17848649 | 0.84 | NR1H2 (0.47) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL26246633 | 0.84 | RORC (0.46) | ALDH1A1LMNAMAPTGPR119 | |
| SCHEMBL23311683 | 0.84 | HDAC2 (0.49) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL17848609 | 0.83 | GPR119 (0.50) | ALDH1A1LMNAMAPTSMN1; SMN2GPR119 | |
| SCHEMBL392783 | 0.82 | ALDH1A1 (0.72) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL31441479 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTKMT2ACYP1A2 | |
| SCHEMBL31441492 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240327351-A1 | AMIDE AND ETHER SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-10-03 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| EP-4204417-A1 | PROTEIN SECRETION INHIBITORS | Kezar Life Sciences (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116194455-A | Protein secretion inhibitor | 科智生命科学公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| WO-2022173805-A1 | AMIDE AND ETHER SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022047347-A1 | PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2021105115-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | ALDH1A1 1823/4885LMNA 4642/4885MAPT 3320/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | ALDH1A1 2551/4885LMNA 4825/4885MAPT 2493/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | ALDH1A1 1919/4885LMNA 4865/4885MAPT 1596/4885 |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | ALDH1A1 4050/4885LMNA 1769/4885MAPT 4822/4885 |
| US-20240327351-A1 | AMIDE AND ETHER SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, AADAC, DNPEP | ALDH1A1 4119/4885LMNA 2292/4885MAPT 2503/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | ALDH1A1 1919/4885LMNA 4865/4885MAPT 1596/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | ALDH1A1 1919/4885LMNA 4865/4885MAPT 1596/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ALDH1A1 4729/4885LMNA 3751/4885MAPT 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.